Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying blaKPC-2 reveals a heterogenous population and reversible genotype

mSphere

Volumn 3, Issue 5, 2018, Pages

  Castanheira, Mariana ^a   Arends, S J Ryan ^a   Davis, Andrew P ^a   Woosley, Leah N ^a   Bhalodi, Amira A ^b,e   MacVane, Shawn H ^c,d,e  

^a JMI LABORATORIES   (United States)

^b ALLERGAN INC   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Accelerate Diagnostics Inc   (United States)

Author keywords

Ceftazidime avibactam; Citrobacter freundii; Resistance mechanism; lactams

Indexed keywords

ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; CEFTAZIDIME;

CITROBACTER FREUNDII; DRUG COMBINATION; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PLASMID;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEFTAZIDIME; CITROBACTER FREUNDII; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PLASMIDS;

EID: 85054363028     PISSN: None     EISSN: 23795042     Source Type: Journal    
DOI: 10.1128/mSphere.00408-18     Document Type: Article

References (15)

1. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. 2017. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 61:e00883. https:// doi.org/10.1128/AAC.00883-17
2. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG, Jr, Paterson DL, Bonomo RA, Evans S, Antibacterial Resistance Leadership Group. 2018. Colistin vs. ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66:163-171. https://doi.org/10.1093/cid/cix783
3. Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, Prince RA, Bhatti MM, Rolston KV, Jones RN, Castanheira M, Chemaly RF. 2016. High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-beta-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center. Clin Infect Dis 63:954-958. https://doi.org/10.1093/cid/ciw398
4. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 59:6605-6607. https://doi.org/10.1128/AAC.01165-15
5. Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S, Sebra R, Kasarskis A, Nguyen H, Hanson BM, Leopold S, Weinstock G, Lomovskaya O, Humphries RM. 2017. Resistance to ceftazidimeavibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother 61:e00989. https://doi.org/10.1128/AAC.00989-17
6. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097. https://doi.org/10.1128/AAC.02097-16
7. Barnes MD, Winkler ML, Taracila MA, Page MG, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA. 2017. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidimeavibactam: unique antibiotic-resistant phenotypes emerge from β-lactamase protein engineering. mBio 8:e00528-17. https://doi.org/10.1128/mBio.00528-17
8. Compain F, Arthur M. 2017. Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 β-lactamase. Antimicrob Agents Chemother 61:e00451. https://doi.org/10.1128/AAC.00451-17
9. Allergan USA, Inc. 2017. AVYCAZ (ceftazidime-avibactam). Allergan USA, Inc, Irvine, CA. https://www.allergan.com/assets/pdf/avycaz_pi. Accessed February 2017
10. CLSI. 2017. M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA
11. Krishnan NP, Nguyen NQ, Papp-Wallace KM, Bonomo RA, van den Akker F. 2015. Inhibition of Klebsiella beta-lactamases (SHV-1 and KPC-2) by avibactam: a structural study. PLoS One 10:e0136813. https://doi.org/10.1371/journal.pone.0136813
12. CLSI. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA
13. CLSI. 2015. M02-A12. Performance standards for antimicrobial disk susceptibility tests, 12th ed. Clinical and Laboratory Standards Institute, Wayne, PA
14. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing Escherichia coli and klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 66:1409-1411. https://doi.org/10.1093/jac/dkr081
15. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. 2014. Epidemiology and carbapenem resistance mechanisms of carbapenemnon-susceptible Pseudomonas aeruginosa collected during 2009-2011 in 14 European and Mediterranean countries. J Antimicrob Chemother 69:1804-1814. https://doi.org/10.1093/jac/dku048